Abstract
Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.
Keywords: Eprosartan, hypertension, sympathetic nervous system, renin angiotensin system
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Volume: 6 Issue: 4
Author(s): P. J. Blankestijn and H. Rupp
Affiliation:
Keywords: Eprosartan, hypertension, sympathetic nervous system, renin angiotensin system
Abstract: Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.
Export Options
About this article
Cite this article as:
Blankestijn J. P. and Rupp H., Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (4) . https://dx.doi.org/10.2174/187152508785909500
DOI https://dx.doi.org/10.2174/187152508785909500 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Simultaneous Determination of Hydrochlorothiazide in Combination with Some Antihypertensive Drugs in The Presence of Its Main Impurities in Pure Form and Pharmaceutical Formulations
Current Pharmaceutical Analysis Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Design and Ocular Tolerance of Flurbiprofen Loaded Nanosuspension
Pharmaceutical Nanotechnology The Phenotypic and Metabolic Characteristics of Neutrophils in Normal Pregnancy and Preeclampsia
Current Immunology Reviews (Discontinued) Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms
Current Aging Science Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Predicting the Activity of ACE Inhibitory Peptides with a Novel Mode of Pseudo Amino Acid Composition
Protein & Peptide Letters The Vasculature as a Target in the Treatment of Pulmonary Emphysema
Current Drug Targets Aging and DNA Methylation
Current Chemical Biology Human Saphenous Vein and Coronary Bypass Surgery: Scanning Electron Microscopy of Conventional and ‘No-Touch’ Vein Grafts
Vascular Disease Prevention (Discontinued) Docking Studies for Multi-Target Drugs
Current Drug Targets Editorial (Hot Topic: Autosomal Dominant Polycystic Kidney Disease: Cardiovascular Complications)
Current Hypertension Reviews Current Update in the Management of Diabetic Nephropathy
Current Diabetes Reviews Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design